Suntegrilin® contains Eptifibatide, an injectable medication belonging to the class of GP IIb/IIIa receptor inhibitors. It is used in emergency cardiac treatments to prevent clot formation. By inhibiting platelet aggregation, this medication prevents complications such as coronary artery occlusion, myocardial infarction (heart attack), and related adverse events in patients with unstable angina or those undergoing angioplasty (PCI). Suntegrilin must be administered exclusively in a hospital setting under the supervision of a cardiologist and specialized medical staff.
Mechanism of Action: Suntegrilin prevents platelet aggregation by inhibiting the GP IIb/IIIa receptor on the surface of platelets, thereby blocking fibrinogen binding.
Clinical Outcomes:
Reduction of thrombus (clot) formation in the vessels.
Prevention of arterial re-closure following angioplasty.
Lowering the risk of heart attack in high-risk patients.
Rapid onset of action, specifically designed for emergency cardiac conditions.
Store at temperatures between 2°C to 8°C.
Do not freeze the medication.
The solution must be clear and free of particles before administration.
For hospital use only.
Significant risk of bleeding exists; use with extreme caution in patients with a high risk of hemorrhage.
Potential interaction with anticoagulants such as Warfarin or Heparin.
Requires special medical attention in cases of:
Uncontrolled hypertension.
History of internal bleeding.
Active bleeding.
Recent surgery.
Use during pregnancy and lactation only under a physician’s discretion.
Contraindications:
Active bleeding or internal hemorrhage.
History of stroke within the past 30 days.
Malignant hypertension.
Severe renal impairment/failure.
Hypersensitivity to Eptifibatide or any of the product’s components.
Common: Bleeding (epistaxis, gingival, or injection site), thrombocytopenia (decreased platelet count), nausea, headache, and hypotension (low blood pressure).
Less Common but Serious: Major internal hemorrhage, large hematoma, allergic reactions, and cardiac arrhythmias.
Note: The patient must be continuously monitored during infusion.
Suntegrilin is supplied in standard hospital boxes containing one 20 mg/10 ml injection vial. The packaging is designed to protect the medication from light, impact, and contamination. Product information, including drug name, composition, dosage, batch number, expiration date, and administration instructions, is accurately and legibly printed on the box. This product is intended for hospital injection and complies with pharmaceutical quality and safety standards.
Reviews
There are no reviews yet.